{
    "ticker": "LGND",
    "name": "Ligand Pharmaceuticals Incorporated",
    "description": "Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies create better medicines. Founded in 1987, Ligand operates a diverse portfolio of commercial products and late-stage clinical assets, leveraging its proprietary technologies to enhance drug development processes. The company's scientific expertise and innovative platforms, such as the Captisol\u00ae technology, improve the solubility and stability of drugs, leading to better therapeutic outcomes. Ligand collaborates with numerous major pharmaceutical companies, enabling them to streamline their drug development efforts and bring new therapies to market efficiently. The company is committed to advancing healthcare solutions across various therapeutic areas, including oncology, infectious diseases, and metabolic disorders. Through strategic partnerships and a robust pipeline, Ligand strives to deliver value to its stakeholders while making significant contributions to global health.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "1987",
    "website": "https://www.ligand.com",
    "ceo": "John D. Higgins",
    "social_media": {
        "twitter": "https://twitter.com/LigandPharma",
        "linkedin": "https://www.linkedin.com/company/ligand-pharmaceuticals/"
    },
    "investor_relations": "https://investors.ligand.com",
    "key_executives": [
        {
            "name": "John D. Higgins",
            "position": "CEO"
        },
        {
            "name": "Matt Foehr",
            "position": "President and COO"
        }
    ],
    "product_categories": [
        {
            "category": "Commercial Products",
            "products": [
                "Captisol\u00ae",
                "Promacta\u00ae",
                "Kyprolis\u00ae"
            ]
        },
        {
            "category": "Development Stage Products",
            "products": [
                "Various Oncology Assets",
                "Infectious Disease Treatments"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ligand Pharmaceuticals | Innovating Drug Development",
        "meta_description": "Ligand Pharmaceuticals is a leader in biopharmaceutical innovation, providing technologies that enhance drug development and improve patient outcomes.",
        "keywords": [
            "Ligand Pharmaceuticals",
            "Biotechnology",
            "Pharmaceuticals",
            "Captisol",
            "Drug Development",
            "Oncology",
            "Infectious Disease"
        ]
    },
    "faq": [
        {
            "question": "What does Ligand Pharmaceuticals do?",
            "answer": "Ligand Pharmaceuticals develops and acquires technologies to assist pharmaceutical companies in creating better medicines."
        },
        {
            "question": "Who is the CEO of Ligand Pharmaceuticals?",
            "answer": "John D. Higgins is the CEO of Ligand Pharmaceuticals."
        },
        {
            "question": "Where is Ligand headquartered?",
            "answer": "Ligand is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Ligand's main products?",
            "answer": "Ligand's main products include Captisol\u00ae, Promacta\u00ae, and Kyprolis\u00ae, along with various developmental assets."
        },
        {
            "question": "When was Ligand founded?",
            "answer": "Ligand was founded in 1987."
        }
    ],
    "competitors": [
        "AMGN",
        "GILD",
        "VRTX",
        "BMY"
    ],
    "related_stocks": [
        "ABBV",
        "JNJ",
        "PFE",
        "MRNA"
    ]
}